Biogen – media

Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe

Biogen expects to launch IMRALDI in Europe on October 16, 2018 Biogen will be the first company to offer biosimilars of all three major anti-TNF therapies in Europe
- Source: businesswire
- 642
- April 9, 2018
AbbVie Biogen biosimilar Samsung Bioepis
New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen)

Biogen (BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA® (nusinersen) among pre-symptomatic infants with spinal muscular atrophy (SMA). In NURTURE, all infants treated with SPINRAZA were alive, did not require permanent ventilation and showed improvement in motor function and motor milestone achievements as of July 5, 2017, compared to the disease’s natural history. This study, along with a case series demonstrating SPINRAZA’s effectiveness among teens and young adults, will be presented at the Muscular Dystrophy Association (MDA) Clinical Conference on March 11-14, 2018, in Arlington, Virginia.
- Source: finance.yahoo
- 2,257
- March 14, 2018
Biogen Clinical Trials SMA SPINRAZA
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis

Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate (MMF) small drug molecule in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (MS).
- Source: businesswire
- 530
- November 29, 2017
ALKS 8700 Biogen Market Views
Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG

Biogen (NASDAQ: BIIB) announced that it has increased the profit potential on aducanumab, its Phase 3 investigational treatment for early Alzheimer’s disease, by reducing the potential royalty payment on potential commercial sales of aducanumab to Neurimmune Holding AG. In exchange for a 15 percent reduction in the previously negotiated royalty rates, Biogen agreed to make a one-time $150 million payment to Neurimmune Holding AG.
- Source: media.biogen
- 480
- October 27, 2017
aducanumab Alzheimer's disease Biogen

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.